Allergan Inc., of Irvine, Calif., gained extended marketing authorization from the European Commission to use Ozurdex (dexamethasone) as a therapy the for the treatment of adults with visual impairment due to diabetic macular edema who have artificial lens implants or are considered insufficiently responsive to, or unsuitable for noncorticosteroids therapy.